In 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 related deaths globally in 2020. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer. (WHO statistics)

  • About 1 in 8 U.S. women will develop invasive breast cancer over the course of their lifetime. In 2022, it is estimated that 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new non-invasive (in situ) breast cancer cases. (www.breastcancer.org)
  • Breast cancer survival for at least 5 years after diagnosis ranges from more than 90% in high-income countries, to 66% in India and 40% in South Africa.
  • Breast cancer mortality showed improvements in survival in the 1980s in countries with early detection programs combined with different modes of treatment to eradicate the invasive disease.

Join the World Affairs Council of Charlotte virtually on Thursday, April 7 as we listen to Dr. Antoinette Tan and Dr. Richard White, two leading experts in breast cancer treatment and research from Levine Cancer Institute. They will share their expert insights into prevention, treatment, and breakthrough developments in breast cancer research in the United States and globally. This discussion will be moderated by Dr. Derek Raghavan, WACC Director and President of the Levine Cancer Institute.

Program Partner: 

Program Information: 

Date:
Thursday, April 7, 2022
Presentation and Q&A: 
1:00 – 2:00 PM E.T.
Cost:
Free

 

 

 

Dr. Antoinette Tan
Antoinette R. Tan, MD, MHSc, is the Chief of Breast Medical Oncology, CoDirector of the Phase I Program, and Chair of the Department of Solid Tumor and Investigational Therapeutics at Levine Cancer Institute, Atrium Health. She is also a Full Professor of Medicine at Levine Cancer Institute, Atrium Health. She graduated from Rutgers University in 1993 with a bachelor’s degree in Biological Sciences. She received her medical degree from Rutgers-Robert Wood Johnson Medical School in 1996 through an accelerated BA/MD program. After completing her internship and residency in internal medicine at North Shore University Hospital–New York University School of Medicine and Memorial Sloan-Kettering Cancer Center, she completed an oncology fellowship at the National Cancer Institute. Dr. Tan also obtained formal training in clinical research during her fellowship and was awarded a Master of Health Sciences degree from Duke University School of Medicine. Her clinical research interests focus on targeted treatments for triple-negative breast cancer and drug development. She has extensive experience in the conduct of early phase clinical trials and phase II and III breast cancer studies.

Dr. Richard White
Richard L. White, Jr., MD, FACS is the Chief of Surgical Oncology, Department of Surgery and Levine Cancer Institute, Professor of Surgery Atrium Health and Endowed Chair of Surgical Oncology. He has served as the Director of the Breast Surgical Oncology Fellowship program. He directs the Breast Metrics Program for the Levine Cancer Institute. He is co-director the Breast and Cutaneous Oncology programs. Dr. White attended Cornell University and Columbia University’s College of Physicians and Surgeons. He received his surgical training at Georgetown University and served as a fellow in surgical oncology and immunotherapy at the National Cancer Institute. Dr. White has served as a member of the Breast Committee of the NSABP, as a member of the Board of Directors of the Alliance for Clinical Trials in Oncology, as the Chair of the American Society of Clinical Oncology Breast Symposium, and on the Executive, Publications, Program and Education Committees of the American Society of Breast Surgeons. He represented the American College of Surgeons on the Commission On Cancer from 2005 – 2011. He is President of the International Sentinel Node Working Group and Chair of the Melanoma Disease Site Working Group of the Society of Surgical Oncology. Dr. White served on the Board of Directors of the American Cancer Society South Atlantic Division for a decade and was awarded the St. George National Award for outstanding service to the community in support of the Society’s mission to combat cancer in 2013. He serves as the American College of Surgeons, State Chair for Commission on Cancer for the state of North Carolina and the American College of Surgeons, North Carolina Chapter, Executive Committee. He was awarded the Outstanding State Chair by the Commission on Cancer in 2021. Locally he serves on the Board of Directors for the Purple Promise Foundation for the Cure of Melanoma. His serves in several roles for the Atrium Health Foundation: Melanoma and Immunotherapy Fund, Founder and Co-Director; the Teresa Flippo, MD, Surgical Oncology Fund, Co-Founder and Board of Directors; Board of Directors of the Breast Fund.

Dr. Derek Raghavan
As the leader of Levine Cancer Institute, Derek Raghavan, MD, PhD, FACP, FRACP, has pioneered an innovative approach to cancer care that eliminates the natural barriers to top-quality care, such as culture, access and distance from clinical and research sites. Before coming to Levine Cancer Institute, he served concurrent appointments as chairman and director of the Taussig Cancer Center at Cleveland Clinic and as the chair in Transitional Cancer Research for the M. Frank and Margaret Domiter Rudy Institute. As an internationally renowned cancer researcher and medical oncologist, Dr. Raghavan has edited nine textbooks, published more than 300 papers in peer-reviewed journals, served on editorial boards of numerous medical journals and been a principal investigator for more than a dozen major research grants.